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Abstract: Aim: Low circulating vitamin D levels are associated with gastric adenocarcinoma, but
whether vitamin D levels are associated with premalignant gastric mucosal changes is unknown.
Here, we determined associations between vitamin D levels and gastric incomplete intestinal
metaplasia, a known gastric adenocarcinoma risk factor. Methods: This was a retrospective,
unmatched, case-control study comparing serum 25-hydroxyvitamin D levels among subjects with
gastric incomplete intestinal metaplasia (cases; n = 103) and those without gastric incomplete
intestinal metaplasia (controls; n = 216). The 25-hydroxyvitamin D levels were categorized as
normal (30–100 ng/dL), vitamin D insufficiency (VDi; 20–29 ng/dL), and vitamin D deficiency
(VDd; <20 ng/dL). Using multivariable logistic regression, odds ratios (ORs) were calculated and
adjusted to age, gender, ethnicity, body mass index, history of hypertension or diabetes mellitus,
and timing of vitamin D collection to assess associations between 25-hydroxyvitamin D levels and
gastric incomplete intestinal metaplasia. Results: A majority of case subjects were male, Hispanic,
and did not have hypertension or diabetes mellitus. The average serum 25-hydroxyvitamin D
level was significantly lower in the intestinal metaplasia group than the control group (19.7 ng/dL
vs. 34.7 ng/dL; p < 0.001). Hypovitaminosis D was more common in subjects with incomplete
intestinal metaplasia in a multivariable regression model (OR 54.1, 95% CI 21.8–134.3; p < 0.001). VDd
(OR 129.0, 95% CI 43.7–381.2; p < 0.001) and VDi (OR 31.0, 95% CI 11.9–80.3; p < 0.001) were more
common in patients with incomplete intestinal metaplasia than healthy subjects, with VDd slightly
more prevalent than VDi (OR 4.0, 95% CI 1.7–9.6; p < 0.001). Conclusions: Vitamin D deficiency
and insufficiency are more common in patients with gastric incomplete intestinal metaplasia than
healthy subjects and may play a role in the development of premalignant phenotypes related to
gastric adenocarcinoma.
Keywords: gastric adenocarcinoma; intestinal metaplasia; vitamin D deficiency
1. Introduction
Gastric adenocarcinoma is the fourth most prevalent cancer worldwide. Patients with gastric
adenocarcinoma are often asymptomatic prior to diagnosis so present with late-stage disease and have
a poor prognosis, the five-year survival rate for advanced disease being less than 30% [1,2]. Chronic
exposure to carcinogens, primarily Helicobacter pylori infection but also to a lesser degree, tobacco
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and alcohol consumption, results in gastric mucosal injury and sequential pathological changes that
ultimately result in gastric adenocarcinoma in the absence of intervention [3,4]. This carcinogenetic
process can be described according to the “Correa cascade”, a model that describes the stepwise
histopathological progression from chronic atrophic gastritis to intestinal metaplasia, gastric dysplasia,
and eventually adenocarcinoma [5].
Intestinal metaplasia is the most frequently observed precancerous change in the gastric mucosa.
Although the absolute risk of progression from gastric intestinal metaplasia to gastric adenocarcinoma
is relatively low in areas of low prevalence for gastric adenocarcinoma like North America and Europe,
the prevalence is higher in other regions of the world including Southeast Asia. Intestinal metaplasia
is characterized by the replacement of the gastric epithelium with intestinal-like epithelium, both of
which are columnar in morphology. There are two subtypes of intestinal metaplasia, complete and
incomplete, the former resembling the small intestine (mucin-rich, intestinal-like columnar epithelium
with goblet cells, a brush border, and eosinophilic enterocytes) and the latter resembling the large
intestine, with distinguishing features including re-expression of gastric mucins and less digestive
enzymes [5]. Incomplete intestinal metaplasia, often considered a mild form of gastric dysplasia [6,7],
carries a 4- to 11-fold increase in risk for the development of gastric adenocarcinoma compared with
complete intestinal metaplasia.
However, enrollment in endoscopic surveillance programs to detect gastric dysplasia and early
gastric adenocarcinoma is controversial, especially in low-prevalence areas including in the United
States. The American Society of Gastrointestinal Endoscopy does not recommend surveillance
endoscopy for patients with gastric intestinal metaplasia unless the patient is otherwise considered high
risk due to a family history or ethnic predisposition. American Journal of Gastroenterology guidelines
recommend surveillance endoscopy with biopsy mapping of the gastric mucosa or serum pepsinogen
levels one year after the index endoscopy, with repeat surveillance endoscopy three years later if there
is extensive intestinal metaplasia, atrophy, or incomplete intestinal metaplasia. The European Society
of Gastrointestinal Endoscopy guidelines recommend surveillance endoscopy in patients with gastric
intestinal metaplasia every three years [7]. Regardless, knowledge and prevention of risk factors [3–5]
for intestinal metaplasia are crucial, because intestinal metaplasia rarely spontaneously regresses
and patients that develop more advanced phenotypes such as gastric dysplasia or adenocarcinoma
require curative but invasive procedures such as endoscopic mucosal resection, endoscopic submucosal
dissection, or gastrectomy, and outcomes are poor with advanced disease.
Vitamin D is a fat-soluble vitamin that, in its biologically active form of 1,25-dihydroxyvitamin D,
has a defined role in bone and calcium metabolism. Due to its known antineoplastic and antioxidant
properties, several studies have explored the association between vitamin D levels and cancer progression.
Indeed, low vitamin D levels are associated with an increased risk of several malignancies including
breast, prostate, colorectal, and pancreatic cancers [8–12], and vitamin D supplementation has been used
for cancer prophylaxis [13]. There is also mounting evidence that low vitamin D levels are associated with
an increased risk of gastric adenocarcinoma and may represent a poor prognostic factor [14]. However,
to our knowledge, the relationship between vitamin D levels and the presence of gastric cancer precursor
lesions such as gastric intestinal metaplasia has yet to be studied. Therefore, here we sought to determine
if vitamin D levels are associated with gastric incomplete intestinal metaplasia.
2. Materials and Methods
2.1. Subjects
Nine hundred and six subjects were recruited after undergoing esophagogastroduodenoscopy
(EGD) during 2015 and 2016. All subjects were aged 18 years or older, had undergone EGD, and had
documented serum 25-hydroxyvitamin D levels from population-based screening from their primary
care provider two months prior to EGD and repletion. The 25-hydroxyvitamin D was selected as the
biomarker of vitamin D levels since it is the predominant form of systemic circulating vitamin D and
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is the best indicator of overall vitamin D stores [15]. Subjects were excluded if they were younger
than 18 years old, did not undergo EGD, did not have a documented serum 25-hydroxyvitamin D
level prior to EGD, consumed alcohol or smoked cigarettes, had a prior surgical procedure involving
the stomach, or had been diagnosed with gastric ulcers, adenomatous polyps, intestinal metaplasia
or dysplasia of the esophagus, dysplasia of the stomach, or a concomitant malignancy (Figure 1).
To ensure that patients did not previously smoke or consume alcohol at any point, multiple visits
logged in the electronic medical record were reviewed to confirm their status for possible exclusion.
All patients were recruited from the gastroenterology practice at Woodhull Medical and Mental
Health Center, an academically affiliated hospital of New York University School of Medicine located in
Brooklyn, NY, USA. This hospital serves a diverse ethnic population with a predominance of Hispanics,
African Americans, and, to a lesser degree, Asian Americans and Caucasians.
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2.2. Design
This was a single-center, retrospective, unmatched, case-control study of subjects who had
undergone EGD and gastric biopsy for evaluation of dyspepsia. Based on the presence or absence
of gastric incomplete intestinal etaplasia after gastric biopsy, patients were designated as either
a control (no g stric intestinal metaplasia) or case (gastric intestinal metaplasia) subject. Serum
25-hydrox vitamin D levels were classified accord ng to defini ions established by th Endocrine
Societ : 30–100 ng/dL was considered normal, with insufficient 25-hydroxyvitamin D levels or
hypovitaminosis D subgrouped into two: vitamin D insufficiency (VDi; 20–29 ng/dL) and vitamin D
deficiency (VDd; <20 ng/dL) [12,15]. Two categories were used to assess timing of vitamin D collection:
fall-winter representing times of less daylight exposure (fall months included September, October,
and November, and winter months included December, January, and February) and spring-summer,
representative of months with more daylight exposure (spring months included March, April, and
May, and sum er months included June, July, and August). These categories were used because
of the retrosp ctive design of this study limiting the ability to reliably measure daylight exposure
among different subjects, in addition to tak ng into a cou t the two-month interval that w s needed to
collect vitamin D levels before EGD. Body mass index (BMI) was categorized according to the World
Health Organization classification: underweight (<18.5 kg/m2), normal (18.5–24.9 kg/m2), overweight
(25–29.9 kg/m2), and obesity class I (30–34.9), class II (35–39.9), and class III (≥40).
The mean and standard deviation (SD) of the case and control subjects’ ages, BMI, and
25-hydroxyvitamin D levels were calculated. Multivariable logistic regression was performed using
IBM SPSS for Windows (version 23; IBM SPSS Inc., Armonk, NY, USA) to calculate odds ratios (ORs) to
assess the association between 25-hydroxyvitamin D levels and gastric incomplete intestinal metaplasia.
ORs were adjusted to confounders including age, gender, ethnicity, BMI, history of diabetes mellitus,
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hypertension, and timing of vitamin D collection, while including the three levels of vitamin D status
as co-variates. To evaluate differences between cases and controls, continuous variables such as age,
BMI, and average serum 25-hydroxyvitamin D levels were assessed using a 2-tailed paired t-test, and
chi-squared analysis was used to test categorical variables such as gender, ethnicity, BMI class, history
of diabetes mellitus or hypertension, and timing of vitamin D collection. A p-value less than 0.05 was
considered statistically significant.
Because this study was retrospective by design, the Biomedical Research Alliance of New York
(BRANY) exempted the study from Institutional Review Board (IRB) review since it met the standards
set forth by the Declaration of Helsinki. Also, requirements for informed consent from subjects were
waived by BRANY because of the retrospective design and complete anonymity of subjects.
3. Results
3.1. Demographic Information
Of the 906 recruited subjects, 319 subjects (approximately 35%) met the inclusion criteria (Figure 1).
Age, gender, ethnicity, BMI, were similar among case and control subjects; case subjects were on average
59.4 years old, 50.5% were male, 68% were Hispanic, 96.1% did not have hypertension, and 87.4% of
patients did not have diabetes mellitus. Among the case subjects, the 25-hydroxyvitamin D levels were
collected predominantly during the spring and summer (75.7%), seasons with more daylight (Table 1).
The control subjects were on average 56.9 years old, Hispanic (64.8%) and consisted of more females
(67.5%). More control subjects had hypertension (18.1% vs. 3.9%) and had vitamin D collections during
the fall and winter seasons (38.4% vs. 24.3%) than the case subjects.
Table 1. Demographic information of case and control subjects.
Intestinal Metaplasia (Cases) No Intestinal Metaplasia (Controls) p-Value
Number of subjects (N) 103 216
Age (years) 59.4 ± 11.6 56.9 ± 13.6 NS 1
<60 years old 49.5% (51) 61.1% (132)
>60 years old 50.5% (52) 38.9% (84)
Gender 0.01
Male 50.5% (52) 32.4% (70)
Female 49.5% (51) 67.5% (146)
Ethnicity NS
Hispanic 68% (70) 64.8% (140)
African American 23.3% (24) 19.0% (41)
Caucasian 4.9% (5) 13.0% (28)
Asian 3.9% (4) 3.2% (7)
Body mass index (BMI; kg/m2) NS
Underweight 3.9% (4) 1.9% (4)
Normal 24.3% (25) 24.1% (52)
Overweight 35.9% (37) 34.7% (75)
Obese (total) 35.9% (37) 39.3% (85)
Obesity Class I 24.3% (25) 20.4% (44)
Obesity Class II 10.7% (11) 12% (26)
Obesity Class III 1% (1) 6.9% (15)
History of Diabetes Mellitus NS
Without Diabetes Mellitus 87.4% (90) 91.7% (198)
With Diabetes Mellitus 12.6% (13) 8.3% (18)
History of hypertension <0.001
Without Hypertension 96.1% (99) 81.9% (177)
With hypertension 3.9% (4) 18.1% (39)
Season of vitamin D
measurement 0.01
Fall-Winter 24.3% (25) 38.4% (86)
Spring-Summer 75.7% (78) 61.6% (133)
1 Abbreviations: NS: Not Significant.
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3.2. Analysis of Vitamin D Status in Intestinal Metaplasia
The majority of control subjects had normal serum vitamin D levels (52.0%; Table 2). Case subjects
with gastric incomplete intestinal metaplasia had a lower average serum 25-hydroxyvitamin D level
(19.7 ng/dL) than control subjects 34.7 ng/dL (p < 0.001; Table 3).
Multivariable logistic regression was performed to assess the impact of confounders such as age,
ethnicity, gender, BMI, diabetes mellitus, hypertension, and timing of vitamin D collection (Table 4).
Hypovitaminosis D was much more common in subjects with gastric incomplete intestinal metaplasia
(OR 54.1, 95% CI 21.8–134.3, p < 0.001; Tables 2 and 4) compared to controls; gender was also statistically
significant in this model (p-value 0.01; Table 4). Of the patients with gastric incomplete intestinal
metaplasia and hypovitaminosis D, VDd (OR 129.0, 95% CI 43.7–381.2, p < 0.001) and VDi (OR 31.0,
95% CI 11.9–80.3, p < 0.001) were more prevalent than normal serum 25-hydroxyvitamin levels in
patients with gastric incomplete intestinal metaplasia, with VDd slightly more prevalent than VDi
(4.0, 95% CI 1.7–9.6, p < 0.001) in this group (Table 2).
Table 2. Comparison of vitamin D states among patients with and without intestinal metaplasia.
Vitamin D Status Intestinal Metaplasia(Cases)
No Intestinal
Metaplasia (Controls)
Normal vitamin D level (30–100 ng/dL) 2.2% (7) 52.0% (166)
Hypovitaminosis D (<30 ng/dL) 97.8% (96) 48.0% (50)
Vitamin D insufficiency (VDi) (20–30 ng/dL) 43.8% (42) 78% (39)
Vitamin D deficiency (VDd) (<20 ng/dL) 56.3% (54) 22% (11)
Odds ratio (95% CI) p-value
Normal vitamin D levels
versus
VDd and VDi 54.1 (21.8–134.3) <0.001
VDd 129.0 (43.7–381.2) <0.001
VDi 31.0 (11.9–80.3) <0.001
VDd versus Vdi 4.0 (1.7–9.6) <0.001
Abbreviations: VDi: vitamin D insufficiency (20–29 ng/dL); VDd: vitamin D deficiency (<20 ng/dL).






Overall vitamin D level (ng/dL) 19.7 ± 6.3 34.7 ± 10.0 <0.001
Variables
Age
<60 years old 19.8 ± 6.5 35.2 ± 11.2 <0.001
>60 years old 19.7 ± 6.3 34.0 ± 8.0 <0.001
Gender
Male 20.4 ± 7.0 34.4 ± 10.4 <0.001
Female 19.9 ± 6.6 34.8 ± 9.9 <0.001
BMI class
Underweight 24.3 ± 2.6 42.0 ± 22.2 0.25
Normal 19.4 ± 6.5 34.5 ± 9.6 <0.001
Overweight 19.7 ± 7.9 35.7 ± 10.8 <0.001
Obese (pooled) 20.4 ± 6.1 33.5 ± 8.8 <0.001
Obesity class I 21.1 ± 6.1 33.9 ± 8.9 <0.001
Obesity class II 19.6 ± 6.4 33.1 ± 9.5 0.03
Obesity class III 20.5 * 33.2 ± 7.4 N/A *







Hispanic 19.3 ± 6.1 34.4 ± 10.8 <0.001
African American 21.5 ± 6.6 34.6 ± 8.1 <0.001
Caucasian 20.9 ± 7.8 36.2 ± 9.5 <0.001
Asian 14.05 ± 3.8 35.2 ± 4.6 <0.001
Blood pressure
Normotensive patients 19.6 ± 6.8 34.8 ± 10.1 <0.001
Hypertensive patients 23.6 ± 6.3 34.4 ± 10.0 <0.001
History of diabetes mellitus
Without diabetes mellitus 19.5 ± 6.3 34.4 ± 9.1 <0.001
With diabetes mellitus 25.7 ± 5.0 38.4 ± 17.33 NS
Timing of Vitamin D Collection
Fall-Winter 22.0 ± 7.3 34.1 ± 9.9 <0.001
Spring-Summer 19.6 ± 6.6 35.0 ± 10.1 <0.001
* One subject with intestinal metaplasia with obesity class III, so a SD could not be calculated for the case subjects
within this class and a t-test could not be performed.
In univariate analyses, among subjects with gastric incomplete intestinal metaplasia, average
25-hydroxyvitamin D levels were generally significantly lower in comparison with the control group
and were generally similar even when divided by subgroup (Table 3). Serum 25-hydroxyvitamin D
levels were even lower in subjects with intestinal metaplasia without hypertension than hypertensive
patients. However, an association between low vitamin D levels and intestinal metaplasia could not be
made in diabetic subjects. Asians (n = 4) with incomplete intestinal metaplasia had the lowest average
25-hydroxyvitamin D levels followed by Hispanic, Caucasian, and African American patients.
Table 4. Multivariable logistic regression analysis including confounders of age, ethnicity, gender, BMI,
history of hypertension or diabetes mellitus, and timing of vitamin D collection.
Variable B Standard Error Wald Statistic p-Value OR, 95% CI
Hypovitaminosis D 4.0 0.46 73.9 <0.001 54.1 (21.8–134.3)
Age 0.004 0.01 0.10 0.76 1.00 (0.98–1.03)
Ethnicity −19.24 2 × 104 3.89 0.27 0.000
Gender −1.00 0.37 7.03 0.008 0.37 (0.18–0.77)
BMI −0.06 0.14 0.17 0.68 0.95 (0.72–1.23)
Diabetes mellitus −1.30 0.84 2.42 0.12 1.40 (0.05–1.40)
Hypertension 0.22 0.51 0.18 0.67 1.24 (0.46–3.35)
Timing of vitamin D collection 0.69 0.38 3.23 0.07 1.99 (0.94–4.23)
Constant −2.92 1.73 2.86 0.1 0.05
4. Discussion
Gastric adenocarcinoma is an aggressive malignancy with a poor prognosis and limited
therapeutic options, especially at later stages. Preventative strategies in at-risk patients involve
avoiding or treating known carcinogenic risk factors. One potential modifiable risk factor is vitamin
D, an antioxidant and anti-cancer agent in vitro [16–25]. Vitamin D arrests carcinogenesis via
upstream modulation of gene transcription by the vitamin D receptor (VDR). After fat-soluble
1,25-dihydroxyvitamin D traverses cell membranes, it binds to cytoplasmic VDR [25] followed by
vitamin D-VDR complex binding to the retinoid X receptor (RXR). This ligand-complex translocates
into the nucleus to bind chromatin and activate transcription via histone acetyl transferase and
ATP-dependent chromatin remodeling to provide transcription factor access to vitamin D response
elements (VDREs) at gene promoters. The downstream functional effects of this pathway include
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induction of apoptosis. In further support of the pathogenetic role of vitamin D in gastric cancer,
subjects with premalignant and malignant histopathological changes were found to have decreased
VDR expression [24]. Further, CD24 mediates gastric adenocarcinoma cell survival and invasion by
activating STAT3 signaling and regulating extracellular matrix protein and VDR expression [20]. Taken
together, these data suggest that reduction of VDR expression may facilitate evasion of apoptosis and
affect the cell cycle to promote carcinogenesis.
Since retrospective studies have demonstrated an association between hypovitaminosis D
(vitamin D insufficiency and deficiency) and gastric adenocarcinoma, low vitamin D levels may also be
associated with other steps in the carcinogenetic pathway [10–12]. However, no study has yet assessed
associations between hypovitaminosis D and pre-malignant histopathological changes in the gastric
mucosa. Here, we fill this knowledge gap by assessing the association between circulating vitamin D
levels and incomplete intestinal metaplasia using a retrospective case-control study design. VDd and
VDi were more common in patients with incomplete intestinal metaplasia than healthy subjects and,
overall, more subjects with incomplete intestinal metaplasia had VDd than VDi. The average serum
25-hydroxyvitamin D level was significantly lower in subjects with incomplete intestinal metaplasia
than in healthy subjects, supporting a hypothesis that low serum vitamin D levels may play a role in
gastric carcinogenesis as early as the intestinal metaplasia stage of development.
In a subgroup analysis, patients with incomplete intestinal metaplasia had lower overall
25-hydroxyvitamin D levels than patients without intestinal metaplasia in all categories except for in
diabetics and included age, gender, ethnicity, BMI, or hypertension. These findings were also relevant
when considering timing of vitamin D collection. Even though collections were predominantly in the
spring and summer, case subjects had lower serum 25-hydroxyvitamin D levels than control subjects in
both groups. In addition, hypovitaminosis D was most common in Asians with incomplete intestinal
metaplasia, but firm conclusions about ethnic differences in serum 25-hydroxyvitamin D levels in
patients with incomplete intestinal metaplasia are difficult to make due to the relatively small sample
size and very few included Asian and Caucasian subjects. Furthermore, although vitamin D levels
may be artificially low in patients with excess adipose tissue, such as in obese subjects, the vitamin D
levels were generally similar in both case and control subjects across BMI classes, so this effect was not
observed in our study.
Our study has several limitations. The sample size was relatively small, so the confidence
intervals were broad, and validation in larger studies will be needed to confirm our observations.
Due to the imbalanced ethnic demography, our studies may not be generalizable to all ethnic groups,
which is particularly important given that gastric adenocarcinoma is most prevalent among Asian
populations [12]. Also, though H. pylori infection is the primary mediator of intestinal metaplasia,
there are other etiological risk factors including even moderate alcohol consumption and cigarette
smoking, and these patient populations were excluded so we cannot generalize our results to these
populations [26,27]. The prevalence of complete intestinal metaplasia varies, with an overall prevalence
of 19%, accounting for 8.2–86% of patients with intestinal metaplasia in some studies [28–30]. In our
population, there was not only a low prevalence of isolated complete intestinal metaplasia but also
gastric dysplasia in the absence of an exclusion criterion; as a result, we could not make conclusions
regarding the association between vitamin D and these other premalignant changes. Lastly, because
this study was retrospective, causality cannot be proven, and prospective studies will be needed
to confirm these initial findings and determine a causative role for hypovitaminosis D and gastric
incomplete intestinal metaplasia.
In conclusion, low serum vitamin D levels may play a role in the development of incomplete
intestinal metaplasia in the gastric mucosa. Future prospective studies are needed to definitively
establish if low vitamin D levels contribute to intestinal metaplasia and, if causation is proven, study
of the mechanism by which hypovitaminosis D mediates carcinogenesis at the stage of intestinal
metaplasia and beyond is warranted. Given these findings, chemoprophylaxis with vitamin D may be
a relatively simple intervention to prevent the development and progression of gastric adenocarcinoma
Nutrients 2018, 10, 629 8 of 9
and should be pursued in interventional trials, not least because other antioxidants such as ascorbic
acid and β-carotene have been shown to be effective for chemoprophylaxis for gastric adenocarcinoma
in patients with intestinal metaplasia [31].
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